Cell Impact resolves on a rights issue of approximately SEK 38.3 million, secures a bridge loan, and diversifies its operations toward additional industrial segments

Cell Impact announced a proposed rights issue of up to approximately SEK 38.3 million at SEK 0.13 per share (record date 4 Feb 2026, subscription 6–20 Feb 2026) to raise net proceeds of ~SEK 33.2m after estimated issue costs of SEK 5.1m. Insiders committed ~SEK 1.3m (3.3%) and external guarantors committed SEK 21.7m (56.7%), leaving the issue ~60% covered; the company has also taken a SEK 12m bridge loan from Fenja Capital with a 4% arrangement fee, 1% monthly interest and warrants that could dilute ~5%. Proceeds are prioritized to repay the bridge loan (36%) and provide working capital (64%) to support commercialization and a strategic expansion from hydrogen flow plates into machine sales and other industrial applications; non-participating shareholders face ~50% dilution on full subscription.

Analysis

Market structure: Cell Impact’s SEK 38.3m rights issue (subscription price SEK 0.13) plus SEK 12m bridge loan and ~60% coverage shifts the company from single-market hydrogen exposure toward machine sales (immediate margin-rich revenue). If machines convert even one mid-sized OEM order in 1H26, cash flow improves materially; failure to convert pushes dilution and potential follow-on financing. ThyssenKrupp collaboration increases commercial reach in Asia and favors industrial OEMs and automation suppliers over pure hydrogen flow-plate specialists.

Risk assessment: Near-term risks (days–weeks) center on EGM approval (30 Jan) and the Information Document (~5 Feb); failure risks rights cancellation or more expensive financing. Mid-term (3–12 months) tail scenarios: guarantors fail to pay (guarantees unsecured), bridge lender enforces warrants (up to ~5% dilution), or EU subsidy shifts further delay hydrogen demand. Hidden dependency: machine order conversion rate and ThyssenKrupp execution – both binary drivers of 2026 revenue.

Trade implications: Direct tactical: current shareholders must decide to subscribe to avoid ~50% dilution (if fully subscribed). If you cannot subscribe, monetize subscription rights (trade window 6–17 Feb). Relative trades: long industrial automation/steel fabricators (e.g., TKA.DE ThyssenKrupp, SAND.ST Sandvik) vs short hydrogen pure-plays (NEL.OL, PCELL.ST, PLUG) for 3–9 months as European subsidy uncertainty persists.

Contrarian angle: Market may underprice machine sales cadence — machines are developed and can deliver immediate cash; if Cell Impact announces a paid machine sale in 1H26, equity upside could be >30% from depressed levels. Conversely, guarantee and bridge terms (15–18% cash/stock compensation, 1% monthly interest) create asymmetric dilution risk; complacent investors who ignore unsecured guarantees will be hurt.

Key Decisions for Investors

• If you are an existing shareholder of Cell Impact (Nasdaq First North): subscribe pro rata in the Rights Issue to maintain exposure (allocate 1–3% of portfolio to retain position) before record date 4 Feb 2026; failing that, sell subscription rights during 6–17 Feb to capture value and avoid ~50% ownership dilution.
• Establish a tactical long (1–2% portfolio) in ThyssenKrupp (TKA.DE) with 6–12 month horizon to play industrial automation/Asia commercialization; target +20–35% upside if machine orders materialize, stop-loss -12%.
• Short or buy puts on hydrogen pure-plays NEL.OL and PLUG (combined 1–2% portfolio) for 3–6 months to hedge policy/subsidy risk; use 3-month 10–15% OTM puts or 1:1 short exposure sized to desired hedge.
• Do not add new long equity exposure to Cell Impact beyond rights participation until proof of machine sale/cash receipt (catalyst window: announcement of machine sale in 1H26 or Information Document ~5 Feb). If a paid machine sale is announced, incrementally add up to +1–2% position within 2 trading days.